within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC24_Mirikizumab;

model Mirikizumab
  extends Pharmacolibrary.Drugs.ATC.L.L04AC24;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L04AC24</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Mirikizumab is a humanized IgG4 monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23). It is developed for the treatment of autoimmune diseases such as moderate to severe ulcerative colitis and Crohn's disease. Mirikizumab has received approval for use in ulcerative colitis in some regions as of 2023.</p><h4>Pharmacokinetics</h4><p>Population-pharmacokinetic model parameters reported for adults with moderate to severe ulcerative colitis after intravenous administration; majority of PK data from phase II and III clinical studies. Subjects included men and women (median age ~40 years).</p><h4>References</h4><ol><li><p>D&#x27;Haens, G, et al., &amp; Sands, BE (2023). Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. <i>The New England journal of medicine</i> 388(26) 2444–2455. DOI:<a href=&quot;https://doi.org/10.1056/NEJMoa2207940&quot;>10.1056/NEJMoa2207940</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37379135/&quot;>https://pubmed.ncbi.nlm.nih.gov/37379135</a></p></li><li><p>Chua, L, et al., &amp; Zhang, XC (2023). Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies. <i>Clinical pharmacokinetics</i> 62(10) 1479–1491. DOI:<a href=&quot;https://doi.org/10.1007/s40262-023-01281-z&quot;>10.1007/s40262-023-01281-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37610533/&quot;>https://pubmed.ncbi.nlm.nih.gov/37610533</a></p></li><li><p>Steere, B, et al., &amp; Krishnan, V (2023). Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study. <i>Clinical and translational gastroenterology</i> 14(7) e00578–None. DOI:<a href=&quot;https://doi.org/10.14309/ctg.0000000000000578&quot;>10.14309/ctg.0000000000000578</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36881820/&quot;>https://pubmed.ncbi.nlm.nih.gov/36881820</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Mirikizumab;
